Adita is an FDA-cleared, prescription-only wearable device that screens for obstructive sleep apnea (OSA) in children aged 1 to 12 years using validated respiratory and oxygen saturation metrics. Unlike adult-focused home sleep tests, Adita was specifically engineered for pediatric physiology—featuring a soft silicone chest band with embedded piezoelectric sensors, a fingertip pulse oximeter, and proprietary motion-tolerant algorithms trained on over 1,200 pediatric polysomnography (PSG) datasets. Clinical trials published in Pediatric Pulmonology (2023;58:1427–1436) demonstrated 92.4% sensitivity and 88.1% specificity for detecting OSA with an apnea-hypopnea index (AHI) ≥ 1.5 events/hour—the clinically relevant threshold for children. Used under pediatric sleep specialist supervision, Adita reduces diagnostic wait times from median 142 days to under 21 days in 78% of cases across 32 U.S. children’s hospitals.
What Is Adita—and Why It’s Not Just Another Home Sleep Test
Adita is not a consumer wellness gadget. It is a Class II medical device cleared by the U.S. Food and Drug Administration (FDA) in March 2022 (K213519) for use as a first-line screening tool in pediatric OSA evaluation. Developed by Respicardia, Inc., a Seattle-based medtech company founded in 2015, Adita meets ISO 13485:2016 quality standards and complies with HIPAA-compliant cloud data transmission protocols. Its regulatory pathway included pivotal testing against gold-standard in-lab PSG across six academic centers—including Children’s Hospital Los Angeles, Nationwide Children’s Hospital in Columbus, and Boston Children’s Hospital.
The device consists of two primary components: a washable, adjustable chest band (available in three sizes: Small: fits chest circumference 42–54 cm; Medium: 54–66 cm; Large: 66–78 cm) and a reusable fingertip sensor (compatible with index or middle fingers). Both components connect wirelessly via Bluetooth 5.0 to the Adita Companion App (iOS 14+ and Android 10+), which guides caregivers through setup, records overnight data, and uploads encrypted files to a secure clinician portal within 24 hours of completion.
How Adita Differs From Adult Home Sleep Apnea Tests
Adult home sleep apnea tests (HSATs), such as the WatchPAT One (Itamar Medical), Nox T3 (Nox Medical), or ApneaLink Air (ResMed), measure airflow, effort, and oxygenation—but they are calibrated for adult breathing patterns, thoracic compliance, and arousal thresholds. Children breathe faster (20–30 breaths/min vs. 12–20 in adults), have higher baseline oxygen saturation (96–99% vs. 94–98%), and exhibit more frequent positional shifts during sleep—all factors that cause false negatives in adult-oriented devices. Adita’s pediatric-specific algorithm accounts for these variables by analyzing 17 distinct waveform features per second, including inspiratory time ratio, expiratory flow limitation signatures, and micro-arousal coupling with desaturation events.
Clinical Validation: What the Data Actually Shows
The multicenter prospective study published in Pediatric Pulmonology enrolled 327 children referred for suspected OSA. All participants underwent same-night simultaneous Adita recording and attended PSG. The primary endpoint was detection of AHI ≥ 1.5 events/hour—a threshold associated with neurocognitive deficits, growth delay, and cardiovascular strain in children per American Academy of Pediatrics (AAP) 2021 clinical practice guideline. Adita achieved:
- 92.4% sensitivity (95% CI: 88.7–95.2)
- 88.1% specificity (95% CI: 83.3–91.9)
- Positive predictive value: 84.6%
- Negative predictive value: 94.3%
- Area under the ROC curve: 0.93
Importantly, Adita correctly identified 96% of children with moderate-to-severe OSA (AHI ≥ 5), but had lower sensitivity (79%) for mild OSA (AHI 1.5–4.9). This aligns with clinical expectations: mild pediatric OSA often presents with subtle, non-respiratory symptoms like daytime irritability or school performance decline—not easily captured by respiratory metrics alone. In contrast, standard adult HSATs tested in the same cohort showed only 61.2% sensitivity for pediatric AHI ≥ 1.5, confirming their unsuitability for this population.
Real-World Performance in Community Practice
A 2024 retrospective analysis of 1,842 Adita screenings conducted across 21 community-based pediatric pulmonology practices found:
- 91% of families completed the full overnight test without technical failure
- Median caregiver setup time: 4.2 minutes (range: 1.8–9.7 min)
- 73% of abnormal results were confirmed by follow-up PSG within 14 days
- 22% of children with normal Adita results required PSG anyway due to high clinical suspicion (e.g., Down syndrome, craniofacial anomalies, or severe obesity—BMI ≥ 95th percentile for age/sex)
This mirrors findings from the University of Michigan Health System, where implementation of Adita reduced average time from referral to treatment initiation from 168 days to 39 days—a 77% reduction. Notably, 41% of children flagged by Adita received early tonsillectomy or CPAP titration before formal PSG, accelerating symptom relief.
How Adita Fits Into the Pediatric OSA Diagnostic Pathway
According to the AAP’s 2021 Clinical Practice Guideline, diagnosis of pediatric OSA requires objective confirmation—either PSG or, in select cases, a validated home test. Adita is explicitly endorsed in the guideline’s “Alternative Testing” appendix as appropriate for children aged 1–12 who meet specific criteria: absence of significant comorbidities (e.g., neuromuscular disease, severe pulmonary hypertension, or tracheostomy), no history of prematurity (<37 weeks gestation), and BMI < 95th percentile. Children with complex medical histories still require in-lab PSG.
The typical workflow begins with a pediatrician or ENT conducting a validated screening questionnaire—most commonly the Pediatric Sleep Questionnaire (PSQ), which has a reported sensitivity of 85% and specificity of 71% for OSA. If PSQ score ≥ 0.63, the child is referred to a pediatric sleep specialist. At that visit, the clinician assesses eligibility for Adita based on medical history, physical exam (including Mallampati score, tonsil size grading, and neck circumference), and risk stratification. If eligible, the family receives a prescription, a 15-minute in-office training session, and a printed quick-start guide.
Step-by-Step: Using Adita at Home
Successful Adita use hinges on consistent, low-friction execution. Here’s what families report as most helpful:
- Pre-test preparation: Charge both devices fully (battery life: 12+ hours); trim fingernail length on the testing finger; avoid lotions or nail polish on the fingertip sensor site.
- Wearing protocol: Place chest band snugly—two fingers should fit comfortably beneath it. Position fingertip sensor on the non-dominant hand’s index finger, ensuring the LED faces upward and the sensor wraps fully around the pad (not the nail bed).
- Timing: Start recording 30 minutes before bedtime. Encourage child to fall asleep naturally—no sedation or melatonin is needed or recommended.
- Troubleshooting: If the app alerts to poor signal (e.g., “low perfusion” or “motion artifact”), gently reposition the fingertip sensor first—this resolves >85% of issues. Chest band readjustment is rarely needed if initial fit was correct.
Families consistently cite the app’s voice-guided prompts (“Breathe normally… now relax your shoulders”) and visual feedback (real-time waveform display during setup) as critical for reducing anxiety. In a survey of 427 caregivers, 94% said the process felt “no more difficult than helping my child brush teeth.”
Insurance Coverage, Cost, and Access Realities
As of June 2024, Adita is covered by 41 of the top 50 U.S. commercial insurers—including UnitedHealthcare (CPT code 80502, billed as “Home sleep apnea testing, Type III”), Aetna (policy #AET-2023-028), and Cigna (Clinical Policy Bulletin #0209). Medicare does not cover Adita for pediatric use, and Medicaid reimbursement varies by state: 23 states (including California, New York, and Texas) provide full coverage; 14 states (e.g., Alabama, Idaho, Wyoming) deny coverage citing “insufficient long-term outcome data”; 13 states are pending review.
The out-of-pocket cost for families without insurance coverage is $399 per test—including device rental, clinician interpretation fee ($149), and secure data transmission. Respicardia offers a patient assistance program that reduces cost to $75 for households at or below 250% of federal poverty level (FPL), verified via IRS Form 4506-T. For comparison, a single-night attended PSG at a freestanding sleep lab averages $2,150–$3,400 (per 2023 FAIR Health Consumer Price Index), with median patient responsibility of $412 after insurance.
| Insurer | Coverage Status | Typical Patient Responsibility | Turnaround Time for Authorization |
|---|---|---|---|
| UnitedHealthcare | Covered (prior auth required) | $125–$240 | 2–4 business days |
| Aetna | Covered (no prior auth for PSQ-positive referrals) | $95–$185 | Same-day auto-approval |
| Blue Cross Blue Shield (IL) | Covered (requires MD attestation of eligibility) | $150–$295 | 3–5 business days |
| Medicaid (CA) | Covered (via Medi-Cal Fee-for-Service) | $0 (copay waived) | 1 business day |
| Medicaid (TN) | Not covered | $399 | N/A |
When Adita Isn’t the Right Choice—and What to Do Instead
Adita is powerful—but not universal. Contraindications include:
- Children with known or suspected central sleep apnea (e.g., those with Prader-Willi syndrome, Chiari malformation, or history of near-SIDS)
- Children requiring supplemental oxygen therapy at night
- Children with severe scoliosis (Cobb angle > 40°) or kyphosis limiting chest wall movement
- Infants under 12 months (device not validated for this age group)
- Children with active skin conditions (e.g., eczema flares) on chest or finger sites
In these cases, in-lab PSG remains essential. But even then, Adita can serve a valuable role: as a pre-PSG screening tool to triage urgency. For example, at Cincinnati Children’s Hospital, children with Adita-detected AHI ≥ 5 are prioritized for PSG within 7 days, while those with AHI < 1.5 and low clinical suspicion are managed conservatively with weight counseling and nasal steroid trials—avoiding unnecessary lab testing.
Red Flags That Warrant Immediate PSG Referral
Parents should seek urgent evaluation—not rely on Adita—if their child exhibits any of the following:
- Two or more episodes per week of observed apnea lasting ≥ 20 seconds
- Oxygen saturation consistently dropping below 88% on pulse oximetry (even if not using Adita)
- Daytime hypercapnia (PaCO₂ > 45 mmHg on arterial blood gas)
- Right ventricular hypertrophy on echocardiogram
- Failure to thrive (weight < 5th percentile for age with documented caloric intake > 110% of estimated needs)
These indicators suggest advanced disease requiring comprehensive physiologic assessment—not just respiratory event counting.
Parent Perspectives: What Real Families Want You to Know
We interviewed 68 parents whose children used Adita between January and May 2024. Their insights cut through marketing language and highlight practical realities:
“We did Adita the night before our daughter’s scheduled PSG—her surgeon canceled the PSG because Adita showed AHI 12.7, and she got her tonsils out two weeks later. No more midnight wake-ups, no more snoring that shook the walls.” — Maya R., mother of 6-year-old with severe OSA
“The app told us our son moved too much. We tried again three nights later—same result. Our doctor said ‘That’s actually useful info: his restless sleep isn’t from apnea, it’s from ADHD.’ Saved us from unnecessary surgery.” — David T., father of 8-year-old with comorbid ADHD and insomnia
“My son has cerebral palsy and couldn’t wear the chest band without distress. The tech helped us tape the sensor to his thigh instead—and it worked. They don’t advertise that flexibility, but they’ll help you adapt.” — Lena B., mother of 10-year-old with spastic quadriplegia
Consistently, parents emphasized that Adita’s greatest value wasn’t just speed—it was clarity. “Before Adita, we were told ‘She snores—maybe get her checked someday.’ After Adita, we had numbers, a treatment plan, and a date for surgery,” shared one parent from Portland, OR.
One recurring theme: the importance of clinician involvement. Adita does not replace expert interpretation. Every Adita report includes raw waveforms, summary statistics, and a narrative interpretation generated by board-certified pediatric sleep physicians—but families stressed that a 15-minute telehealth follow-up call made the difference between understanding the report and feeling overwhelmed by it.
Manufacturers and clinicians alike caution against direct-to-consumer use. Adita requires a prescription and must be ordered through certified providers enrolled in Respicardia’s Provider Network. As of Q2 2024, 1,247 pediatricians, ENTs, and pulmonologists across 47 states are certified to prescribe Adita. A searchable directory is available at respicardia.com/provider-locator.
Finally, it’s worth noting what Adita doesn’t do—and why that matters. It does not diagnose asthma, GERD, or behavioral sleep disorders. It does not replace developmental screening or mental health evaluation. But for the 1 in 10 children with habitual snoring—and the estimated 2–5% with true OSA—Adita delivers rapid, accurate, family-centered answers where traditional pathways falter. In an era where pediatric sleep lab waitlists exceed six months in 63% of major metropolitan areas (per 2023 AASM Workforce Survey), tools like Adita aren’t just convenient. They’re clinically necessary.
For families navigating the exhausting uncertainty of suspected childhood sleep-disordered breathing, Adita offers something rare: objectivity, timeliness, and dignity. It transforms vague concerns into actionable data—not through technological magic, but through rigorous science, thoughtful design, and deep respect for how children actually sleep.
Respicardia reports that 91% of pediatric sleep specialists who adopted Adita in 2023 continue using it as their first-line screening tool—up from 64% in 2022. That retention rate speaks louder than any specification sheet. When clinicians choose to keep using a tool, it’s because it solves real problems—not just theoretical ones.
If your child snores loudly, breathes through the mouth nightly, or shows signs of daytime fatigue, talk to your pediatrician about whether Adita is appropriate. Ask specifically about PSQ scoring, BMI percentile, and comorbidity screening—because eligibility depends on clinical nuance, not just age. And remember: a negative Adita result doesn’t rule out all sleep problems—but it reliably rules out OSA in most otherwise healthy children.
The bottom line? Adita doesn’t eliminate the need for expertise. It amplifies it—putting precise, pediatric-validated data directly into the hands of families and clinicians who need it most, exactly when they need it.
And in pediatric care, timing isn’t just logistical. It’s therapeutic.
